vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
+$0.50 today
- Market cap
- $64.17M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
Volume 0.02M
Average 0.05M
VTVT Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
vTv Therapeutics Inc.NASDAQ: VTVT
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $13.58M rose 108.7% year over year, ahead of the +59.2% change in trailing-twelve-month operating expenses. Sequentially, it rose 72.2% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +108.7% holds above the trailing-twelve-month pace of +59.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 32.81M USD
- Year-over-year change
- +30.2%
- 4-year CAGR
- +6.3%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.81M | +30.2% |
| FY2024 | 2024-12-31 | 25.2M | -1.2% |
| FY2023 | 2023-12-31 | 25.5M | +3.8% |
| FY2022 | 2022-12-31 | 24.56M | -4.3% |
| FY2021 | 2021-12-31 | 25.67M | — |
Operating Expenses vs competitors
How VTVT compares with its peers on the latest reported figures
- VTVT's LTM Mar 2026 operating expenses of $39.88M is the 4th highest of the 9 companies compared; the peer median is $33.76M.
- Its year-over-year change of +59.2% is the 2nd highest of 9, against a peer median of -12.7%.
- Operating expenses amounts to 108.3% of revenue for VTVT, versus a peer median of 497.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $98.5M | -27.0% | -23.2% | 148.9% | |
| LTM Mar 2026 | $59.37M | -22.3% | +2.5% | 17821.9% | |
| LTM Jun 2026 | $43.72M | -39.4% | -5.5% | 208.2% | |
| LTM Mar 2026 | $39.88M | +59.2% | +10.1% | 108.3% | |
| LTM Mar 2026 | $34.01M | -44.2% | -8.3% | — | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $33.51M | +199.7% | +85.4% | — |
| LTM Mar 2026 | $19.69M | -3.2% | +1.5% | — | |
| LTM Mar 2026 | $18.04M | +2.8% | -27.4% | 786.8% | |
| LTM Mar 2026 | $12.67M | +38.6% | -26.4% | — | |
| Peer median (excluding VTVT) | $33.76M | -12.7% | -6.9% | 497.5% | |
Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.01M | 2.02M | 0 | 1.02M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 4.01M | 2.02M | 0 | 1.02M | 0 |
| Gross Margin | 100.0% | 100.0% | — | 100.0% | — |
| Research & Development | 13.32M | 12.36M | 13.6M | 11.55M | 17.86M |
| Selling, General & Admin | 12.34M | 12.2M | 11.91M | 13.65M | 14.95M |
| Operating Expenses | 25.67M | 24.56M | 25.5M | 25.2M | 32.81M |
| Depreciation & Amortization | 89K | 92K | 90K | 89K | 16K |
| EBITDA | (17.52M) | (24.77M) | (25.86M) | (22.52M) | (31.06M) |
| EBITDA Margin | -437.3% | -1227.3% | — | -2214.0% | — |
| Operating Income | (21.66M) | (22.54M) | (25.5M) | (24.18M) | (32.81M) |
| Operating Margin | -540.9% | -1116.9% | — | -2377.6% | — |
| Interest Income | 1K | 352K | 472K | 1.57M | 1.87M |
| Interest Expense | 12K | 15K | 13K | 0 | 6K |
| Other Income / Expenses | 4.05M | (2.33M) | (464K) | 1.58M | 1.73M |
| Income Before Tax | (17.62M) | (24.87M) | (25.97M) | (22.61M) | (31.08M) |
| Pre-Tax Margin | -439.9% | -1232.6% | — | -2222.7% | — |
| Income Tax Expense | 115K | 200K | 0 | 100K | 0 |
| Net Income | (12.99M) | (19.16M) | (20.25M) | (18.46M) | (26.97M) |
| Net Margin | -324.3% | -949.7% | — | -1815.3% | — |
| EPS (Basic) | (8.29) | (9.98) | (9.71) | (3.20) | (3.20) |
| EPS (Diluted) | (8.29) | (9.98) | (9.71) | (3.20) | (3.20) |
| Weighted Avg Shares | 1.57M | 1.92M | 2.08M | 5.77M | 8.42M |
| Weighted Avg Shares (Diluted) | 1.57M | 1.92M | 2.08M | 5.77M | 8.42M |
vTv Therapeutics Inc.
NASDAQ:VTVT
Intrinsic Alpha fair value
Locked
Current Price
$16.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.